O’Melveny’s Bush Quoted in Compliance Week on China Healthcare

January 14, 2014 A January 14, 2014, Compliance Week article, titled “China Ups Scrutiny of Healthcare Industry, Expands Blacklist,” quoted O’Melveny & Myers partner Nate Bush.  The piece focuses on China's National Health and Family Planning Commission's (NHFPC) “blacklist,” which limits or blocks drug and medical device producers and their agents from selling products in the country.  “The new blacklist raises the risks that miss-steps by individual employees anywhere in China can jeopardize sales everywhere in China,” Bush explained in the article, adding “in principle, more vigorous enforcement by Chinese authorities of domestic anti-corruption rules may actually deter corrupt conduct in a sector long-plagued by allegations of bribery.”

Bush resides in the Firm’s Singapore office and is a member of O’Melveny’s Antitrust and Competition Practice.